DaiLai Technologies Secures Series A Funding Led by Fengyu Capital with MedBio Capital as Exclusive Financial Advisor

VCBeat has learned that Fong Capital Partners has completed its first-round investment in Beijing Dalai Technology Co., Ltd., with MedBio Capital serving as the exclusive financial advisor.

Schematic Diagram of the Company's Business Model

There remains an unmet clinical need in the intervention and management of Parkinson’s disease. First-line pharmacological therapies are limited by the “wearing-off” phenomenon and the “on-off” phenomenon, resulting in suboptimal control of motor symptoms in patients at moderate to advanced stages, while invasive surgical procedures are associated with significant trauma and numerous adverse effects. Against the backdrop of population aging, extended life expectancy for Parkinson’s patients, and rising expectations for quality of life, non-invasive wearable diagnostic and therapeutic devices can enable more effective and personalized regulation and intervention for various motor symptoms—such as tremor, rigidity, and freezing of gait—through chronic disease management approaches, thereby establishing a new paradigm for lifelong intervention and management of Parkinson’s disease.

Previously, non-invasive wearable devices for the diagnosis and treatment of Parkinson’s disease were confined to small-scale laboratory-level research and validation, lacking large-scale studies to confirm their efficacy. However, with Cala Health’s Cala Trio achieving large-scale clinical validation for tremor improvement and securing FDA approval, alongside the preliminary efficacy validation of Charco Neurotech’s CUE1 in pilot studies, non-invasive assistive devices for Parkinson’s disease are gradually gaining recognition among physicians and patients worldwide.

Drawing on the team’s extensive clinical experience, Dalai Technology has proposed a novel hypothesis of “Peripheral Vibrotactile Stimulation–Coordinated Resetting” and developed a proprietary wearable device for peripheral neuromodulation. Related clinical research findings are forthcoming in a top-tier journal in the field. Unlike the more common wearable devices for Parkinson’s disease that focus on tremor improvement or monitoring, this product directly addresses freezing of gait—a challenging symptom for both pharmacological treatments and conventional wearables—thus holding substantial market potential. Furthermore, the company has developed a series of wearable neuromodulation products targeting various motor and non-motor symptoms of Parkinson’s disease, committed to achieving lifecycle-wide intervention and management to comprehensively enhance patients’ quality of life.

The funds raised in this financing round will be allocated to product R&D, regulatory registration, team expansion, and the construction of production facilities, thereby advancing clinical trials and regulatory approvals for core products and laying the foundation for subsequent industrialized commercialization.

Fong Capital Partners is a dual-currency equity investment firm focused on the healthcare and technology sectors, with offices in Beijing, Shanghai, and Hong Kong. The core team at Fong Capital has collaborated for over 10 years, possessing extensive experience in managing both RMB and USD funds, with assets under management exceeding RMB 8 billion. The firm boasts rich industrial resources in the healthcare and technology sectors. Adhering to an investment philosophy of sustained focus, precise allocation, and deep industry engagement, the Fong team has delivered stable and consistent superior returns to investors over the past decade, earning continued recognition from numerous domestic and international institutional investors.

Fong Capital Partners is committed to empowering its portfolio companies through comprehensive support across industry-academia-research collaboration, clinical resources, sales channels, and regulatory affairs. Acting as a true partner, the firm leverages its professional expertise to drive corporate growth. Notable past investments include Sonoscape Medical Corp. (Stock Code: 300633, a leader in medical ultrasound and endoscopic equipment), DJI Innovations (the world’s leading drone brand), Transsion Holdings (Stock Code: 688036, the number one mobile phone brand in Africa), Ronbay Technology (Stock Code: 688005, a Chinese R&D manufacturer of cathode materials for power lithium batteries), and BMC Medical Co., Ltd. (Stock Code: 301367, China’s leading brand in home respiratory care devices).

MedBio Capital is a boutique investment bank focused on the life sciences and healthcare sectors, dedicated to becoming the capital and strategic partner of top-tier scientists and entrepreneurs. Its core team has deep expertise in the medical industry, covering key stages from R&D and clinical development to market commercialization, and possesses composite backgrounds in investment, investment banking, and consulting. Team members have collectively facilitated over RMB 10 billion in financing and have served more than ten leading publicly listed healthcare companies.